Fig. 6: Molecular associations with clinical benefit and response. | Nature Communications

Fig. 6: Molecular associations with clinical benefit and response.

From: Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer

Fig. 6

a Clinical benefit to chemotherapy and b immunotherapy are shown as stacked bar plots with No-Benefit (progressive disease) (black) and clinical benefit (complete response, partial response, and stable disease) (red) displayed by subtype. Bars are the proportion of patients within each subtype, n represents the absolute number in the group. Clinical benefit to ICI plotted by c TMB (n = 157 samples) and IGS scores (n = 176 samples) for d Ayers T cell inflamed GEP and Ayers IFNG, e Bindea B-cells, GO BCR signaling, Iglesia B cell cluster, and f CIBERSORTx proportions of follicular helper T cells, naïve CD4 T cells, and M1 macrophages. All boxplots are shown with boxes representing the IQR and midline at the median. Error bars represent Q1/Q3  ±  1.5 × IQR. Two-sided Wilcoxon p-values are shown above the comparison. Clinical benefit and response, along with KM plots for overall survival to chemotherapy or immunotherapy are shown for patients who had tumors with either g, h ERCC2 mutations or i, j FANCC, ATM, and RB1 mutations. Source data are provided as a Source Data file.

Back to article page